APO Research
Talk to an analyst

APO RESEARCH · REPORT

Varicella Live Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Varicella Live Vaccine Market Outlook and Growth Opportunities 2026

20 December 2025196 pages

Choose your research edition.

Industry ResearchVaricella Live Vaccine Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Live Vaccine Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Varicella Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Live Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Live Vaccine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Varicella Live Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Varicella Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Varicella Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Varicella Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Varicella Live Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Varicella Live Vaccine market include Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Sanofi Pasteur, Panacea Biotec, Mitsubishi Tanabe Pharma Corporation and MedImmune, LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Varicella Live Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Varicella Live Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Varicella Live Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Varicella Live Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Varicella Live Vaccine Segment by Company

Johnson & Johnson

Merck & Co., Inc.

Pfizer, Inc.

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

Sanofi Pasteur

Panacea Biotec

Mitsubishi Tanabe Pharma Corporation

MedImmune, LLC

Emergent BioSolutions, Inc.

Daiichi Sankyo

CSL Limited

Biological E

Bavarian Nordic

Astellas Pharma Inc.

Varicella Live Vaccine Segment by Type

Monovalent Vaccines

Multivalent Vaccines

Varicella Live Vaccine Segment by Application

Herpes Zoster Immunization

Measles Immunization

Chicken Pox Immunization

Others

Varicella Live Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Varicella Live Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Varicella Live Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Varicella Live Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Varicella Live Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Live Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Live Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Varicella Live Vaccine industry.

Chapter 3: Detailed analysis of Varicella Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Varicella Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Varicella Live Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Varicella Live Vaccine Industry Trends Table 2. Varicella Live Vaccine Industry Drivers Table 3. Varicella Live Vaccine Industry Opportunities and Challenges Table 4. Varicella Live Vaccine Industry Restraints Table 5. Global Varicella Live Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Varicella Live Vaccine Revenue Share by Company (2021-2026) Table 7. Global Varicella Live Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Varicella Live Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Varicella Live Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Varicella Live Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Varicella Live Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Varicella Live Vaccine Company, Product Type & Application Table 13. Global Varicella Live Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Varicella Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Monovalent Vaccines Table 18. Significant Companies of Multivalent Vaccines Table 19. Global Varicella Live Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Varicella Live Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Varicella Live Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Varicella Live Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Varicella Live Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Varicella Live Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Varicella Live Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Varicella Live Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Varicella Live Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Varicella Live Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Herpes Zoster Immunization Table 30. Significant Companies of Measles Immunization Table 31. Significant Companies of Chicken Pox Immunization Table 32. Significant Companies of Others Table 33. Global Varicella Live Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Varicella Live Vaccine Sales Volume by Application (2021-2026) & (k units) Table 35. Global Varicella Live Vaccine Sales Volume by Application (2027-2032) & (k units) Table 36. Global Varicella Live Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Varicella Live Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Varicella Live Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Varicella Live Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Varicella Live Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Varicella Live Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Varicella Live Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Varicella Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Varicella Live Vaccine Sales by Region (2021-2026) & (k units) Table 45. Global Varicella Live Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Varicella Live Vaccine Sales by Region (2027-2032) & (k units) Table 47. Global Varicella Live Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Varicella Live Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Varicella Live Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Varicella Live Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Varicella Live Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Varicella Live Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Varicella Live Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Varicella Live Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Varicella Live Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Varicella Live Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Varicella Live Vaccine Sales by Country (2021-2026) & (k units) Table 58. Global Varicella Live Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Varicella Live Vaccine Sales by Country (2027-2032) & (k units) Table 60. Global Varicella Live Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Varicella Live Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Varicella Live Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Varicella Live Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Varicella Live Vaccine Sales Value Market Share by Country (2027-2032) Table 65. Johnson & Johnson Company Information Table 66. Johnson & Johnson Business Overview Table 67. Johnson & Johnson Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Johnson & Johnson Varicella Live Vaccine Product Portfolio Table 69. Johnson & Johnson Recent Development Table 70. Merck & Co., Inc. Company Information Table 71. Merck & Co., Inc. Business Overview Table 72. Merck & Co., Inc. Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Merck & Co., Inc. Varicella Live Vaccine Product Portfolio Table 74. Merck & Co., Inc. Recent Development Table 75. Pfizer, Inc. Company Information Table 76. Pfizer, Inc. Business Overview Table 77. Pfizer, Inc. Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Pfizer, Inc. Varicella Live Vaccine Product Portfolio Table 79. Pfizer, Inc. Recent Development Table 80. GlaxoSmithKline plc Company Information Table 81. GlaxoSmithKline plc Business Overview Table 82. GlaxoSmithKline plc Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. GlaxoSmithKline plc Varicella Live Vaccine Product Portfolio Table 84. GlaxoSmithKline plc Recent Development Table 85. Serum Institute of India Pvt. Ltd. Company Information Table 86. Serum Institute of India Pvt. Ltd. Business Overview Table 87. Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product Portfolio Table 89. Serum Institute of India Pvt. Ltd. Recent Development Table 90. Sanofi Pasteur Company Information Table 91. Sanofi Pasteur Business Overview Table 92. Sanofi Pasteur Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Sanofi Pasteur Varicella Live Vaccine Product Portfolio Table 94. Sanofi Pasteur Recent Development Table 95. Panacea Biotec Company Information Table 96. Panacea Biotec Business Overview Table 97. Panacea Biotec Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Panacea Biotec Varicella Live Vaccine Product Portfolio Table 99. Panacea Biotec Recent Development Table 100. Mitsubishi Tanabe Pharma Corporation Company Information Table 101. Mitsubishi Tanabe Pharma Corporation Business Overview Table 102. Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product Portfolio Table 104. Mitsubishi Tanabe Pharma Corporation Recent Development Table 105. MedImmune, LLC Company Information Table 106. MedImmune, LLC Business Overview Table 107. MedImmune, LLC Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. MedImmune, LLC Varicella Live Vaccine Product Portfolio Table 109. MedImmune, LLC Recent Development Table 110. Emergent BioSolutions, Inc. Company Information Table 111. Emergent BioSolutions, Inc. Business Overview Table 112. Emergent BioSolutions, Inc. Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Emergent BioSolutions, Inc. Varicella Live Vaccine Product Portfolio Table 114. Emergent BioSolutions, Inc. Recent Development Table 115. Daiichi Sankyo Company Information Table 116. Daiichi Sankyo Business Overview Table 117. Daiichi Sankyo Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Daiichi Sankyo Varicella Live Vaccine Product Portfolio Table 119. Daiichi Sankyo Recent Development Table 120. CSL Limited Company Information Table 121. CSL Limited Business Overview Table 122. CSL Limited Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. CSL Limited Varicella Live Vaccine Product Portfolio Table 124. CSL Limited Recent Development Table 125. Biological E Company Information Table 126. Biological E Business Overview Table 127. Biological E Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Biological E Varicella Live Vaccine Product Portfolio Table 129. Biological E Recent Development Table 130. Bavarian Nordic Company Information Table 131. Bavarian Nordic Business Overview Table 132. Bavarian Nordic Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Bavarian Nordic Varicella Live Vaccine Product Portfolio Table 134. Bavarian Nordic Recent Development Table 135. Astellas Pharma Inc. Company Information Table 136. Astellas Pharma Inc. Business Overview Table 137. Astellas Pharma Inc. Varicella Live Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Astellas Pharma Inc. Varicella Live Vaccine Product Portfolio Table 139. Astellas Pharma Inc. Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Varicella Live Vaccine Distributors List Table 143. Varicella Live Vaccine Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Varicella Live Vaccine Product Image Figure 2. Global Varicella Live Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Varicella Live Vaccine Sales (2021-2032) & (k units) Figure 5. Global Varicella Live Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Varicella Live Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Monovalent Vaccines Image Figure 10. Multivalent Vaccines Image Figure 11. Global Varicella Live Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Varicella Live Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Varicella Live Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Varicella Live Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Varicella Live Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Varicella Live Vaccine Sales Value Share by Type (2021-2032) Figure 17. Herpes Zoster Immunization Image Figure 18. Measles Immunization Image Figure 19. Chicken Pox Immunization Image Figure 20. Others Image Figure 21. Global Varicella Live Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Varicella Live Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Varicella Live Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Varicella Live Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Varicella Live Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Varicella Live Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Varicella Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Varicella Live Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Varicella Live Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Varicella Live Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Varicella Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Varicella Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Varicella Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Varicella Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Varicella Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Varicella Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Varicella Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Varicella Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Varicella Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Varicella Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Varicella Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Varicella Live Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Varicella Live Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Monovalent Vaccines
  • Multivalent Vaccines
Applications
  • Herpes Zoster Immunization
  • Measles Immunization
  • Chicken Pox Immunization
  • Others
Companies covered
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Sanofi Pasteur
  • Panacea Biotec
  • Mitsubishi Tanabe Pharma Corporation
  • MedImmune, LLC
  • Emergent BioSolutions, Inc.
  • Daiichi Sankyo
  • CSL Limited
  • Biological E
  • Bavarian Nordic
  • Astellas Pharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Varicella Live Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Varicella Live Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Varicella Live Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Varicella Live Vaccine Market Dynamics
  1. 2.1 Varicella Live Vaccine Industry Trends
  2. 2.2 Varicella Live Vaccine Industry Drivers
  3. 2.3 Varicella Live Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Live Vaccine Industry Restraints
3 Varicella Live Vaccine Market by Company
  1. 3.1 Global Varicella Live Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Varicella Live Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Varicella Live Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Varicella Live Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Varicella Live Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Varicella Live Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Varicella Live Vaccine Company Product Type and Application
  8. 3.8 Global Varicella Live Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Varicella Live Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Varicella Live Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Varicella Live Vaccine Market by Type
  1. 4.1 Varicella Live Vaccine Type Introduction
  2. 4.1.1 Monovalent Vaccines
  3. 4.1.2 Multivalent Vaccines
  4. 4.2 Global Varicella Live Vaccine Sales Volume by Type
  5. 4.2.1 Global Varicella Live Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Varicella Live Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Varicella Live Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Varicella Live Vaccine Sales Value by Type
  9. 4.3.1 Global Varicella Live Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Varicella Live Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Varicella Live Vaccine Sales Value Share by Type (2021-2032)
5 Varicella Live Vaccine Market by Application
  1. 5.1 Varicella Live Vaccine Application Introduction
  2. 5.1.1 Herpes Zoster Immunization
  3. 5.1.2 Measles Immunization
  4. 5.1.3 Chicken Pox Immunization
  5. 5.1.4 Others
  6. 5.2 Global Varicella Live Vaccine Sales Volume by Application
  7. 5.2.1 Global Varicella Live Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Varicella Live Vaccine Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Varicella Live Vaccine Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Varicella Live Vaccine Sales Value by Application
  11. 5.3.1 Global Varicella Live Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Varicella Live Vaccine Sales Value by Application (2021-2032)
  13. 5.3.3 Global Varicella Live Vaccine Sales Value Share by Application (2021-2032)
6 Varicella Live Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Varicella Live Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Varicella Live Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Varicella Live Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Varicella Live Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Varicella Live Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Varicella Live Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Varicella Live Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Varicella Live Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Varicella Live Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Varicella Live Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Varicella Live Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Varicella Live Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Varicella Live Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Varicella Live Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Varicella Live Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Varicella Live Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Varicella Live Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Varicella Live Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Varicella Live Vaccine Sales Value Share by Country, 2025 VS 2032
7 Varicella Live Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Varicella Live Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Varicella Live Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Varicella Live Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Varicella Live Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Varicella Live Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Varicella Live Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Varicella Live Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Varicella Live Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Varicella Live Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Varicella Live Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Varicella Live Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Varicella Live Vaccine Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Varicella Live Vaccine Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Pfizer, Inc.
  14. 8.3.1 Pfizer, Inc. Company Information
  15. 8.3.2 Pfizer, Inc. Business Overview
  16. 8.3.3 Pfizer, Inc. Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer, Inc. Varicella Live Vaccine Product Portfolio
  18. 8.3.5 Pfizer, Inc. Recent Developments
  19. 8.4 GlaxoSmithKline plc
  20. 8.4.1 GlaxoSmithKline plc Company Information
  21. 8.4.2 GlaxoSmithKline plc Business Overview
  22. 8.4.3 GlaxoSmithKline plc Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline plc Varicella Live Vaccine Product Portfolio
  24. 8.4.5 GlaxoSmithKline plc Recent Developments
  25. 8.5 Serum Institute of India Pvt. Ltd.
  26. 8.5.1 Serum Institute of India Pvt. Ltd. Company Information
  27. 8.5.2 Serum Institute of India Pvt. Ltd. Business Overview
  28. 8.5.3 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product Portfolio
  30. 8.5.5 Serum Institute of India Pvt. Ltd. Recent Developments
  31. 8.6 Sanofi Pasteur
  32. 8.6.1 Sanofi Pasteur Company Information
  33. 8.6.2 Sanofi Pasteur Business Overview
  34. 8.6.3 Sanofi Pasteur Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur Varicella Live Vaccine Product Portfolio
  36. 8.6.5 Sanofi Pasteur Recent Developments
  37. 8.7 Panacea Biotec
  38. 8.7.1 Panacea Biotec Company Information
  39. 8.7.2 Panacea Biotec Business Overview
  40. 8.7.3 Panacea Biotec Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Panacea Biotec Varicella Live Vaccine Product Portfolio
  42. 8.7.5 Panacea Biotec Recent Developments
  43. 8.8 Mitsubishi Tanabe Pharma Corporation
  44. 8.8.1 Mitsubishi Tanabe Pharma Corporation Company Information
  45. 8.8.2 Mitsubishi Tanabe Pharma Corporation Business Overview
  46. 8.8.3 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product Portfolio
  48. 8.8.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
  49. 8.9 MedImmune, LLC
  50. 8.9.1 MedImmune, LLC Company Information
  51. 8.9.2 MedImmune, LLC Business Overview
  52. 8.9.3 MedImmune, LLC Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 MedImmune, LLC Varicella Live Vaccine Product Portfolio
  54. 8.9.5 MedImmune, LLC Recent Developments
  55. 8.10 Emergent BioSolutions, Inc.
  56. 8.10.1 Emergent BioSolutions, Inc. Company Information
  57. 8.10.2 Emergent BioSolutions, Inc. Business Overview
  58. 8.10.3 Emergent BioSolutions, Inc. Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Emergent BioSolutions, Inc. Varicella Live Vaccine Product Portfolio
  60. 8.10.5 Emergent BioSolutions, Inc. Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Varicella Live Vaccine Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 CSL Limited
  68. 8.12.1 CSL Limited Company Information
  69. 8.12.2 CSL Limited Business Overview
  70. 8.12.3 CSL Limited Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 CSL Limited Varicella Live Vaccine Product Portfolio
  72. 8.12.5 CSL Limited Recent Developments
  73. 8.13 Biological E
  74. 8.13.1 Biological E Company Information
  75. 8.13.2 Biological E Business Overview
  76. 8.13.3 Biological E Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Biological E Varicella Live Vaccine Product Portfolio
  78. 8.13.5 Biological E Recent Developments
  79. 8.14 Bavarian Nordic
  80. 8.14.1 Bavarian Nordic Company Information
  81. 8.14.2 Bavarian Nordic Business Overview
  82. 8.14.3 Bavarian Nordic Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bavarian Nordic Varicella Live Vaccine Product Portfolio
  84. 8.14.5 Bavarian Nordic Recent Developments
  85. 8.15 Astellas Pharma Inc.
  86. 8.15.1 Astellas Pharma Inc. Company Information
  87. 8.15.2 Astellas Pharma Inc. Business Overview
  88. 8.15.3 Astellas Pharma Inc. Varicella Live Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Pharma Inc. Varicella Live Vaccine Product Portfolio
  90. 8.15.5 Astellas Pharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Varicella Live Vaccine Value Chain Analysis
  2. 9.1.1 Varicella Live Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Varicella Live Vaccine Sales Mode & Process
  6. 9.2 Varicella Live Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Varicella Live Vaccine Distributors
  9. 9.2.3 Varicella Live Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst